Allergan drafts football star Von Miller to expand glaucoma awareness push

Super Bowl MVP Von Miller is Allergan's newest spokesman in its ongoing campaign to raise awareness around glaucoma. (Allergan)

Allergan has added Super Bowl MVP Von Miller to its glaucoma awareness roster. The Denver Broncos linebacker and healthy vision advocate is suiting up for the “My Glaucoma” campaign, serving as a spokesman in media interviews and online.

Miller, who suffered with vision problems as a child, notes in an online video, “I don’t have glaucoma, but I do know what it’s like to struggle with eyesight and the frustration it causes.”

In the video at MyGlaucoma.com, Miller talks about his battles with low self-esteem and quality-of-life issues people with vision problems experience. On the page, Miller also encourages people to take an “eye” Q test about glaucoma in a friendly competition to be an MVP like him.

RELATED: Rapper Common joins Allergan to warn in rhyme—and swirling color—about vision loss

“We wanted to find the right person to really help amplify the awareness of this disease and the impact it can have. Not only on patients, but also on their caregivers. Von was a natural selection for us,” said Matthew Bolton, Allergan's executive director of glaucoma marketing.

Miller has his own charity, Von’s Vision, to provide Denver-area kids with eye exams and glasses. He’s also known as a 2016 contestant on “Dancing With the Stars.”

Since the campaign began in October, its website has garnered 100,000 views, and Bolton expects more as Miller’s spokesman role continues. Miller has been interviewed on media including ABC News and CBS, and he's shared the video on Instagram, racking up more than 60,000 likes. Social media commenters pitched in their own stories, too.

RELATED: Eye-med maker Allergan takes on preventable blindness with nationwide vision-screening push

Allergan, which markets glaucoma-fighting treatments Lumigan and Alphagan, began the campaign with a study in conjunction with the Glaucoma Research Foundation. They found that while 3 in 4 patients are concerned they will lose their vision to glaucoma, 40% consider it to be only somewhat serious or not serious at all.

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.